Efficacy of the Sinopharm Vaccine Against COVID-19

Vaccines developed with two different inactivated strains of SARS-CoV-2 (Sinopharm) significantly reduced the risk of symptomatic cases of COVID-19 with an excellent safety profile. Its proven technology—already used against other virus (influenza, hepatitis, polio, rabies)—and the fact that they can be stored at 2-8 °C mean that they are easily (and cheaply) produced, stored, and administered.

Eficacia de la vacuna Sinopharm contra el COVID-19

This interim analysis was included in the protocol of the randomized, double-blind trial that included over 40,000 participants aged 18 and over.

Participants were randomized to receive the inactivated vaccine with the WIV04 strain (5 µg/dose, n = 13,459) or the HB02 strain (4 µg/dose, n = 13,465), while the control group was inoculated with aluminum hydroxide (n = 13,458). Aluminum hydroxide was used as control because it is the vehicle used in the active vaccines. All participants received two intramuscular injections 21 days apart.

The primary endpoint of the trial was laboratory-confirmed symptomatic infection 14 days after the second dose. For the safety analysis, only one dose was sufficient (this design is similar to that of other trials).

After 77 days of follow-up, 26 participants in the WIV04 strain arm, 21 in the HB02 strain arm, and 95 controls tested positive for COVID-19.

This yields an efficacy of 72.8% and 78.1% for vaccines developed with the WIV04 and the HB02 strains, respectively (p < 0.001 for both).


Read also: COVID-19 Risk in Vaccinated Healthcare Workers.


No vaccinated participant suffered from severe COVID-19, and adverse events were rare and similar among all three groups.

Conclusion

This pre-specified analysis shows that both inactivated vaccines reduce significantly the risk of symptomatic COVID-19 disease.

jama-Sinopharm

Original Title: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. A Randomized Clinical Trial.

Reference: Nawal Al Kaabi et al. JAMA. 2021 May 26. Online ahead of print. doi: 10.1001/jama.2021.8565. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is the Booster Dose Against COVID-19 Effective for All Ages?

The answer is incontrovertible: it is undeniably effective. For all ages, the confirmed COVID19 and severe case rates were significantly lower for patients who...

Pfizer Booster Dose Efficacy against Omicron

The BNT162b2 vaccine (Pfizer/BioNTech) has previously shown a 95% efficacy against COVID-19. This efficacy has been changing with the surge of new variants and,...

Once Again, the Omicron Variant Tests the Limits of Healthcare Systems, But with Hope

The latest significant COVID-19 variant, the Omicron, is again pushing healthcare systems around the world onto the verge of collapse, having reached over 300...

The Most Read Articles of 2021: COVID-19

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on COVID-19. Follow...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...